3[1]Herold C I,Blackwell K L.The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormoneresponsive breast cancer.Breast,2008,17:S15-S24.
4[2]Doisneau Sixou S F,Serqio C M,Carroll J S,et al.Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.Endocr Relat Cancer,2003,10:179-186.
5[3]Waeber M,Castiqlione Gertsch M,Dietrich D,et al.Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence:definitive results of a phase Ⅲ randomized trial(SAKK23/82)comparing tamoxifen with observation.Ann Oncol,2003,14:1215-1221.
6[4]Fisher B,Dignam J,Bryant J,et al.Five versus more than five years of tamoxifen for lymph node-negative breast cancer:updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial.J Natl Cancer Inst,2001,93:684-90.
7[6]Mouridsen H,Gershanovich M.The role of aromatase inhibitors inthe treatment of metastatic breast cancer.Semin Oncol,2003,30:33-45.
8[7]Del Mastro L,Clavarezza M,Venturini M.Reducing the risk of distant metastases in breast cancer patients:role of aromatase inhibitors,2007,33:681-687.
9[8]Ficker J.Letrozole better than tamoxifen in postmenopausal women.Lancet Oncol,2005,6:137-138.
10[9]Pennery E.The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.Eur J Oncol Nurs,2008,[Epub ahead of print].
